Literature DB >> 17975025

Comprehensive and rapid genotyping of mutations and haplotypes in congenital bilateral absence of the vas deferens and other cystic fibrosis transmembrane conductance regulator-related disorders.

Corinne Bareil1, Caroline Guittard, Jean-Pierre Altieri, Carine Templin, Mireille Claustres, Marie des Georges.   

Abstract

Available commercial kits only screen for the most common cystic fibrosis transmembrane conductance regulator (CFTR) mutations causing classic cystic fibrosis and for the Tn variant in IVS8. However, full scanning of CFTR is needed for the diagnosis of patients with cystic fibrosis or CFTR-related disorders (including congenital bilateral absence of the vas deferens) bearing rare mutations. Standard strategies for detecting point mutations rely on extensive scanning of the gene by denaturing gradient gel electrophoresis or denaturing high performance liquid chromatography, which are time-consuming. Moreover, the haplotyping of IVS8-(TG)m and Tn tracts is still challenging despite several recent improvements. We have optimized both the detection of mutations and the haplotyping of IVS8 polyvariants in developing two methods: i) a rapid and robust direct sequence analysis of all exons/flanking introns of the CFTR gene based on single condition touchdown amplification/sequencing in 96-well plates, and ii) a fluorescent assay that allows haplotyping of IVS8-(TG)mTn even without family linkage study. Combined with search for rare large rearrangements, this strategy detected 87.9% of CFTR defects in congenital bilateral absence of the vas deferens patients, a proportion considerably higher than those usually reported. These highly efficient tests, scanning each sample in a few days, greatly improve the genotyping of patients with CFTR-related symptoms and may be particularly important in emergency situations such as fetus with hyperechogenic bowel suggestive of cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975025      PMCID: PMC2049054          DOI: 10.2353/jmoldx.2007.070040

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  31 in total

1.  Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.

Authors:  T Dörk; B Dworniczak; C Aulehla-Scholz; D Wieczorek; I Böhm; A Mayerova; H H Seydewitz; E Nieschlag; D Meschede; J Horst; H J Pander; H Sperling; F Ratjen; E Passarge; J Schmidtke; M Stuhrmann
Journal:  Hum Genet       Date:  1997-09       Impact factor: 4.132

2.  Rapid detection of CFTR gene rearrangements impacts on genetic counselling in cystic fibrosis.

Authors:  F Niel; J Martin; F Dastot-Le Moal; B Costes; B Boissier; V Delattre; M Goossens; E Girodon
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

3.  'Touchdown' PCR to circumvent spurious priming during gene amplification.

Authors:  R H Don; P T Cox; B J Wainwright; K Baker; J S Mattick
Journal:  Nucleic Acids Res       Date:  1991-07-25       Impact factor: 16.971

4.  Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.

Authors:  H Cuppens; W Lin; M Jaspers; B Costes; H Teng; A Vankeerberghen; M Jorissen; G Droogmans; I Reynaert; M Goossens; B Nilius; J J Cassiman
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

5.  Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.

Authors:  Joshua D Groman; Timothy W Hefferon; Teresa Casals; Lluís Bassas; Xavier Estivill; Marie Des Georges; Caroline Guittard; Monika Koudova; M Daniele Fallin; Krisztina Nemeth; Gyorgy Fekete; Ludovit Kadasi; Ken Friedman; Martin Schwarz; Cristina Bombieri; Pier Franco Pignatti; Emmanuel Kanavakis; Maria Tzetis; Marianne Schwartz; Giuseppe Novelli; Maria Rosaria D'Apice; Agnieszka Sobczynska-Tomaszewska; Jerzy Bal; Manfred Stuhrmann; Milan Macek; Mireille Claustres; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

6.  Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions.

Authors:  P Fanen; N Ghanem; M Vidaud; C Besmond; J Martin; B Costes; F Plassa; M Goossens
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

7.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

8.  A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype.

Authors:  M Chillón; T Dörk; T Casals; J Giménez; N Fonknechten; K Will; D Ramos; V Nunes; X Estivill
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

9.  Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms.

Authors:  Marie-Pierre Audrézet; Jian-Min Chen; Odile Raguénès; Nadia Chuzhanova; Karine Giteau; Cédric Le Maréchal; Isabelle Quéré; David N Cooper; Claude Férec
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

10.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations.

Authors:  W E Highsmith; L H Burch; Z Zhou; J C Olsen; T E Boat; A Spock; J D Gorvoy; L Quittel; K J Friedman; L M Silverman
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

View more
  8 in total

Review 1.  Evaluation of the azoospermic male.

Authors:  Robert Oates
Journal:  Asian J Androl       Date:  2011-12-19       Impact factor: 3.285

2.  A balance between activating and repressive histone modifications regulates cystic fibrosis transmembrane conductance regulator (CFTR) expression in vivo.

Authors:  Anne Bergougnoux; Isabelle Rivals; Alessandro Liquori; Caroline Raynal; Jessica Varilh; Milena Magalhães; Marie-José Perez; Nicole Bigi; Marie Des Georges; Raphaël Chiron; Ahmed Saad Squalli-Houssaini; Mireille Claustres; Albertina De Sario
Journal:  Epigenetics       Date:  2014-04-29       Impact factor: 4.528

3.  Identification of the second CFTR mutation in patients with congenital bilateral absence of vas deferens undergoing ART protocols.

Authors:  Rossella Giuliani; Ivana Antonucci; Isabella Torrente; Paola Grammatico; Giandomenico Palka; Liborio Stuppia
Journal:  Asian J Androl       Date:  2010-07-26       Impact factor: 3.285

4.  WGA allows the molecular characterization of a novel large CFTR rearrangement in a black South African cystic fibrosis patient.

Authors:  Marie des Georges; Caroline Guittard; Carine Templin; Jean-Pierre Altiéri; Candice de Carvalho; Michele Ramsay; Mireille Claustres
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

Review 5.  External and Genetic Conditions Determining Male Infertility.

Authors:  Piotr Kamiński; Jędrzej Baszyński; Izabela Jerzak; Brendan P Kavanagh; Ewa Nowacka-Chiari; Mateusz Polanin; Marek Szymański; Alina Woźniak; Wojciech Kozera
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

6.  Quantitative Evaluation of CFTR Pre-mRNA Splicing Dependent on the (TG)mTn Poly-Variant Tract.

Authors:  Manuela Sterrantino; Andrea Fuso; Silvia Pierandrei; Sabina Maria Bruno; Giancarlo Testino; Giuseppe Cimino; Antonio Angeloni; Marco Lucarelli
Journal:  Diagnostics (Basel)       Date:  2021-01-25

7.  CFTR gene variants in Indian congenital bilateral absence of vas deferens & its relevance in genetic counselling.

Authors:  Ashutosh Halder; Deepak Pandey
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

Review 8.  Genetic evaluation of male infertility.

Authors:  Matthew S Wosnitzer
Journal:  Transl Androl Urol       Date:  2014-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.